A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
Clinical trial NCT06891833 · RECRUITING
Trial details
- NCT number
- NCT06891833
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-05
- Primary completion
- 2028-12-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.